This site is intended for healthcare professionals
News

AbbVie presents new efficacy data on Rinvoq in people with active psoriatic arthritis and axial involvement.

Read time: 1 mins
Last updated:11th Nov 2021
Published:11th Nov 2021
AbbVie announced results from new post-hoc analyses from the Phase III SELECT-PsA 1 and SELECT-PsA 2 trials assessing the efficacy of upadacitinib (Rinvoq) on axial symptoms in adult patients with active psoriatic arthritis (PsA) and axial involvement.

The analysis showed that patients with active PsA demonstrated numerically greater clinical responses related to their axial involvement with upadacitinib (15 mg, once daily) compared to placebo at week 24 across both studies and consistently numerically higher responses compared to Humira (adalimumab) at week 24 in SELECT-PsA 1.

Axial involvement was defined by investigator assessment and patient-reported-outcome-based criteria (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) greater than 4 and BASDAI Question 2 greater then 4 at baseline). These results were featured at the American College of Rheumatology (ACR) Convergence 2021, in an oral presentation on Tuesday, Nov. 9, from 3:30-3:45 p.m. CT (Abstract #1945).

As previously reported, in SELECT-PsA 1, through week 24, serious infections occurred in 1.2% of patients in the 15 mg Rinvoq group compared to 0.9% in the placebo group and 0.7% in the Humira group. There were no cases of adjudicated venous thromboembolic events (VTE) in the Rinvoq 15 mg group, two cases in the adalimumab group (0.5%) and one case in the placebo group (0.2%). No major adverse cardiovascular events (MACE) were reported in the Rinvoq 15 mg group. There was one MACE reported in the placebo group and two MACE reported in the Humira group. Herpes zoster was reported in four cases in the 15 mg Rinvoq group (0.9%), three cases in the placebo group (0.7%) and no cases in the Humira group. There were no deaths in the Rinvoq 15 mg group, one death in the placebo group (0.2%) and no deaths in the adalimumab group.

As previously reported, for the SELECT-PsA 2 study, through week 24, serious infections occurred in 0.5% of patients in the Rinvoq 15 mg group compared to 0.5% in the placebo group. There was one pulmonary embolism reported in the 15 mg Rinvoq and none in the placebo group. There was one non-fatal adjudicated major adverse cardiovascular event (MACE) in the 15 mg Rinvoq group (acute myocardial infarction) and no MACE in the placebo group. Herpes zoster was reported in three cases in the 15 mg Rinvoq group (1.4%) and in two cases in the placebo group (0.9%). One death was reported in a patient receiving placebo (motor vehicle accident).

Condition: Psoriatic Arthritis
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.